



CORPORATE NEWSLETTER

2nd November 2024

Dear Cannioasis Team,

1. Leadership Updates: Appointment of New CEO and COO

We are thrilled to announce the appointment of our CEO, Jon Lim, and COO, Alfred Tan. Each brings a wealth of experience and dynamic leadership to our executive team as we work toward accelerated growth and innovation.

Jon Lim, Chief Executive Officer

Holds an MBA with a specialization in entrepreneurship and finance, Jon Lim has more than 20 years of experiences in business management, corporate finance and strategic planning in both foreign and local MNCs including KLA, Merrill Lynch, Inventec Besta, Pacific Internet, OCBC Bank, Agilent Technologies and HL Display. In his last role as CFO, Asia Pacific he managed in excess of 500 employees over 10 countries, ensuring they are not only profitable but also a leader in their field. He has worked extensively in the USA, Sweden, Germany, Switzerland, and the Asia Pacific region served as a Professional Management Consultant (PMC) and a consultant of Intellectual Property Office of Singapore (IPOS).

Alfred Tan, Chief Operating Officer

With a MBA background, Alfred Tan has spearheaded operational transformations and optimized performance in high-growth environments. Armed with 20 years of experience in marketing, operations, and consultancy across health, wellness, lifestyle, and e-commerce sectors, Alfred was instrumental in creating a comprehensive range of supplements and wellness services, in partnership with prominent wellness organizations such as CXA, Body with Soul, Complete Health International (Asia Medic) and Gravity (Fitness First). As our COO, he will be responsible for managing day-to-day operations, enhancing our operational efficiencies, and implementing systems to support our scaling efforts. Alfred is a Certified Agile Practitioner and a Singapore Certified Management Consultant (SCMC).

2. Reverse Takeover (RTO) Progress and Fundraising Update

Our RTO plan is progressing smoothly, with an ongoing audit to ensure we meet all compliance and operational standards. We target to complete the audit by November 2024 and will work on the other TSX requirements in parallel including confirming the local counsel, finalising the Canada's reporting manager. Our plan is to obtain TSX approval by end 2024 so that we can RTO by Q1 2025.

In addition, we are performing a fundraising of CAD 5million to support our RTO and strategic initiatives. The company will be issuing CAD 5 million in 20% preferred shares at CAD 0.16 per share. This is a 20% discount to the valuation from TSX of CAD 0.20 per share. This step will fortify our resources as we position ourselves for future growth. We appreciate the confidence our investors have shown in our vision and capabilities. Note: Funds will be held in escrow until RTO approval. For more information, please approach Jon Lim.



3. Highlight on Technological Assets

As we continue to invest in technology to support our growth, we've made significant progress in enhancing our technological assets.

At CanniOasis, we've developed unique technology that can create 3D brain cell structures from stem cells, specifically mimicking cells found in the midbrain—one of the brain areas affected by Parkinson's Disease (PD). Unlike traditional lab methods that use flat, 2D cell cultures, our 3D approach allows these cells to grow in a way that's closer to how they exist in the human brain. This lets us study more realistic cellular behaviours and interactions.

One remarkable finding from our research is that our 3D brain cell models can produce neuromelanin, a pigment normally found in midbrain cells affected by PD. This pigment is challenging to study because it's usually only accessible through human brain tissue after death upon autopsy or otherwise and could not be tracked on a life diseased brain tissue. By recreating these cells in the lab, we're opening up new possibilities to understand the role of neuromelanin in PD. Our technology could offer a valuable tool for studying how Parkinson's develops and even lead to personalized treatments or potential cures in the future.

Thank you for your hard work and dedication. Together, with new leadership, enhanced technological resources, and robust strategic initiatives, we are on a path to an incredible future. Let's continue to make progress and create positive impact, one step at a time.

Warm regards,
Dr. Lim Kah Meng
Founder/Non-Exec Chairman/Chief Scientific Advisor
CanniOasis

In collaboration with the Corporate Communications Team